Stock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-market on Strong Q2 Results and Raised Revenue Guidance

Stock Track

Jul 29, 2025

Kiniksa Pharmaceuticals Ltd. (KNSA) shares surged 7.77% in pre-market trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.

The biopharmaceutical company reported Q2 earnings per share (EPS) of $0.23, surpassing the analyst estimate of $0.18. Kiniksa's Q2 sales reached $156.797 million, exceeding the expected $145.218 million. The company's net income for the quarter stood at $17.832 million, with a pretax profit of $22.877 million, showcasing robust financial performance.

In a significant move, Kiniksa raised its 2025 net product revenue guidance for ARCALYST, its flagship product. The company now expects ARCALYST to generate between $625 million and $640 million in revenue for the year, up from the previous guidance of $590 million to $605 million. This upward revision signals strong confidence in the drug's market performance and potential growth. Additionally, Kiniksa announced the initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, further bolstering its pipeline prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1135013027"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135013027\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135013027?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135013027","market":"sg","top_or_hot":-1,"title":"Stock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-market on Strong Q2 Results and Raised Revenue Guidance","media":"Stock Track","content":"<p>Kiniksa Pharmaceuticals Ltd. (KNSA) shares surged 7.77% in pre-market trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.</p>\n\n<p>The biopharmaceutical company reported Q2 earnings per share (EPS) of $0.23, surpassing the analyst estimate of $0.18. Kiniksa's Q2 sales reached $156.797 million, exceeding the expected $145.218 million. The company's net income for the quarter stood at $17.832 million, with a pretax profit of $22.877 million, showcasing robust financial performance.</p>\n\n<p>In a significant move, Kiniksa raised its 2025 net product revenue guidance for ARCALYST, its flagship product. The company now expects ARCALYST to generate between $625 million and $640 million in revenue for the year, up from the previous guidance of $590 million to $605 million. This upward revision signals strong confidence in the drug's market performance and potential growth. Additionally, Kiniksa announced the initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, further bolstering its pipeline prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-market on Strong Q2 Results and Raised Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-market on Strong Q2 Results and Raised Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-07-29 19:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kiniksa Pharmaceuticals Ltd. (KNSA) shares surged 7.77% in pre-market trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.</p>\n\n<p>The biopharmaceutical company reported Q2 earnings per share (EPS) of $0.23, surpassing the analyst estimate of $0.18. Kiniksa's Q2 sales reached $156.797 million, exceeding the expected $145.218 million. The company's net income for the quarter stood at $17.832 million, with a pretax profit of $22.877 million, showcasing robust financial performance.</p>\n\n<p>In a significant move, Kiniksa raised its 2025 net product revenue guidance for ARCALYST, its flagship product. The company now expects ARCALYST to generate between $625 million and $640 million in revenue for the year, up from the previous guidance of $590 million to $605 million. This upward revision signals strong confidence in the drug's market performance and potential growth. Additionally, Kiniksa announced the initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, further bolstering its pipeline prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNSA","symbol_name":"Kiniksa Pharmaceuticals Ltd.","start_time":0,"source_url":"","article_id":"1135013027","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135013027","pubTimestamp":1753789459,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Kiniksa Pharmaceuticals Ltd. (KNSA) shares surged 7.77% in pre-market trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"个股追踪|Kiniksa Pharmaceuticals盘前大涨7.77%，Q2业绩强劲，营收指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":1},"content_text":"Kiniksa Pharmaceuticals Ltd. (KNSA) shares surged 7.77% in pre-market trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.\nThe biopharmaceutical company reported Q2 earnings per share (EPS) of $0.23, surpassing the analyst estimate of $0.18. Kiniksa's Q2 sales reached $156.797 million, exceeding the expected $145.218 million. The company's net income for the quarter stood at $17.832 million, with a pretax profit of $22.877 million, showcasing robust financial performance.\nIn a significant move, Kiniksa raised its 2025 net product revenue guidance for ARCALYST, its flagship product. The company now expects ARCALYST to generate between $625 million and $640 million in revenue for the year, up from the previous guidance of $590 million to $605 million. This upward revision signals strong confidence in the drug's market performance and potential growth. Additionally, Kiniksa announced the initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, further bolstering its pipeline prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}